Scientists working to develop a comparatively easy, inexpensive way to give patients with bladder cancer a better idea of likely outcome and best treatment options, found that sophisticated new molecular subtyping techniques designed to do that provide no better information than long-standing pathology tests. They looked at several datasets of cancer specimens from patients with muscle invasive bladder cancer, a high-grade cancer associated with high mortality. They consistently found that molecular subtyping - now offered to patients - was outperformed by standard tests used to characterize bladder cancer as low- or high-grade and to determine the extent of its invasion into the bladder wall and beyond. They suggest more study is needed before subtypes are used to help guide patient care.